<DOC>
	<DOCNO>NCT00957229</DOCNO>
	<brief_summary>The purpose study reduce number new surgically eligible BCCs 50 % appear month 3-18 medication ingestion .</brief_summary>
	<brief_title>To Determine The Efficacy Safety GDC-0449 Patients With Basal Cell Nevus Syndrome ( BCNS )</brief_title>
	<detailed_description>This Phase II , 18 month , double blind , randomize placebo-controlled , two arm multicenter clinical study design . During 18-month treatment period , safety chemopreventive efficacy 150 mg/day GDC-0449 versus placebo assess , include evaluation skin monthly interval first three month every 3 month next 15 month . Removal new surgically eligible BCCs ( SEBs ) do primary skin care physician ( PSCPs ) Study Centers . A Data Safety Monitoring Board ( DSMB ) review unblinded result interim analysis 20 subject complete 12 month drug . This review focus adverse event efficacy result . Subjects monitor development new SEBs discontinue study treatment . At end 18 month , give observed adverse event minimal , patient placebo offer opportunity take GDC-0449 18 month open label continuation , follow six month observation , patient GDC449 monitor next 24 month assessment duration benefit stop drug .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nevus</mesh_term>
	<mesh_term>Nevus , Pigmented</mesh_term>
	<mesh_term>Basal Cell Nevus Syndrome</mesh_term>
	<criteria>The subject : diagnose least 10 SEB ( diameter 3 mm diameter great nose periorbital skin , 5 mm great elsewhere face , 9 mm great nonfacial area exclude skin knee ) two year study entry , document histologically physician ' record and/or diagnose clinically Study Investigator baseline . meet diagnostic criterion basal cell nevus syndrome willing abstain application nonstudy topical medication skin duration study , include prescription counter preparation . Subjects encourage use sunscreen ( SPF 15 ) least daily expose skin site . willing forego treatment BCCs unless BCCs document Study Investigators , preferably two separate visit , except PSCP believe delay treatment potentially might compromise health subject . normal laboratory test define follow : Normal hematopoietic capacity , Normal hepatic function : AST ALT great equal 2x upper limit normal ( ULN ) Total bilirubin within normal range 0.20 mg/dl 1.50 mg/dl within 3x ULN patient Gilbert 's disease Normal renal function : normal serum creatinine measure creatinine clearance le 50 mL/minute . Fasting cholesterol great equal 220 untreated willing donate blood semen three month follow discontinuation Study medication . willing avoid pregnancy partner define follow : Male subject willing use latex condom study 3 month last dose sexual contact female childbearing potential , even successful vasectomy . His partner must also use form birth control The subject : used topical systemic therapy might interfere evaluation study medication study . Specifically include use : ( ) glucocorticoids 5 % skin ( ii ) retinoids systemically topically 5 % skin six month prior study entry ; ( iii ) alphahydroxy acid 5 % skin six month prior study entry ( iv ) 5fluorouracil imiquimod systemically topically skin knee six month prior study entry . ( v ) treatment systemic chemotherapy within one year prior start study medication . history hypersensitivity ingredient study medication formulation . unable return followup visit test . uncontrolled systemic disease , include know HIV positive patient . history congestive heart failure . uncontrolled hypocalcemia , hypomagnesemia , hypokalemia clinically important history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis . condition situation Investigator 's opinion may put subject significant risk , could confound study result , could interfere significantly subject 's participation study . history invasive cancer within past five year exclude nonmelanoma skin cancer , Stage I cervical cancer , ductal carcinoma situ breast , CLL Stage 0. current , recent ( within 4 week Day 1 ) , plan participation experimental drug study enrol study . female pregnant , plan ever become pregnant , capable become pregnant breast feeding . male unwilling unable comply pregnancy prevention measure .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>